Latest & greatest articles for mammography

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on mammography or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on mammography and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for mammography

61. Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: further evidence of benefit

Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: further evidence of benefit Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: further evidence of benefit Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: further evidence of benefit Maurice A, Evans DG, Affen J, Greenhalgh R, Duffy SW, Howell A Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of clinical breast examination, before conventional mammography, for women at a high risk of breast cancer, given their family history. The authors concluded that clinical

Full Text available with Trip Pro

2013 NHS Economic Evaluation Database.

62. Population Screening Act: mammography in two directions as standard

Population Screening Act: mammography in two directions as standard Population Screening Act: mammography in two directions as standard Population Screening Act: mammography in two directions as standard Health Council of the Netherlands Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Council of the Netherlands. Population Screening Act: mammography (...) in two directions as standard. The Hague: Health Council of the Netherlands Gezondheidsraad (GR). 2013/07. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Early Detection of Cancer; Mammography; Mass Screenings Language Published English Country of organisation Netherlands English summary An English language summary is available. Address for correspondence Postbus 16052, 2500 BB Den Haag, The Netherlands. Tel: +31 70 340 7520;Fax: +31 70 340 7523

2013 Health Technology Assessment (HTA) Database.

63. Observational study: Mammography screening in Norway caused substantial overdiagnosis and did not reduce late-stage breast cancers

Observational study: Mammography screening in Norway caused substantial overdiagnosis and did not reduce late-stage breast cancers Mammography screening in Norway caused substantial overdiagnosis and did not reduce late-stage breast cancers | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Mammography screening in Norway caused substantial overdiagnosis and did not reduce late-stage breast cancers Article Text Online articles Observational

2013 Evidence-Based Medicine (Requires free registration)

64. A false-positive on screening mammography has a negative psychosocial impact up to 3?years after receiving the all clear

A false-positive on screening mammography has a negative psychosocial impact up to 3?years after receiving the all clear A false-positive on screening mammography has a negative psychosocial impact up to 3 years after receiving the all clear | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A false-positive on screening mammography has a negative psychosocial impact up to 3 years after receiving the all clear Article Text

2013 Evidence-Based Mental Health

65. Citations of scientific results and conflicts of interest: the case of mammography screening (PubMed)

Citations of scientific results and conflicts of interest: the case of mammography screening Citations of scientific results and conflicts of interest: the case of mammography screening | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Citations of scientific results and conflicts of interest: the case of mammography screening Article Text Original EBM Research Citations of scientific results and conflicts of interest: the case

Full Text available with Trip Pro

2013 Evidence-Based Medicine (Requires free registration)

66. Effect of three decades of screening mammography on breast-cancer incidence. (PubMed)

Effect of three decades of screening mammography on breast-cancer incidence. To reduce mortality, screening must detect life-threatening disease at an earlier, more curable stage. Effective cancer-screening programs therefore both increase the incidence of cancer detected at an early stage and decrease the incidence of cancer presenting at a late stage.We used Surveillance, Epidemiology, and End Results data to examine trends from 1976 through 2008 in the incidence of early-stage breast cancer (...) (ductal carcinoma in situ and localized disease) and late-stage breast cancer (regional and distant disease) among women 40 years of age or older.The introduction of screening mammography in the United States has been associated with a doubling in the number of cases of early-stage breast cancer that are detected each year, from 112 to 234 cases per 100,000 women--an absolute increase of 122 cases per 100,000 women. Concomitantly, the rate at which women present with late-stage cancer has decreased

Full Text available with Trip Pro

2012 NEJM

67. Use of prior mammograms in the transition to digital mammography: a performance and cost analysis

Use of prior mammograms in the transition to digital mammography: a performance and cost analysis Use of prior mammograms in the transition to digital mammography: a performance and cost analysis Use of prior mammograms in the transition to digital mammography: a performance and cost analysis Taylor-Phillips S, Wallis MG, Duncan A, Gale AG Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to examine the costs and the detection performance of digital mammography, with or without previous film mammograms, in the UK NHS breast screening programme. The authors concluded that either digitised or non-digitised film mammograms improved the performance of digital screening and saved costs by reducing the number of normal cases who

2012 NHS Economic Evaluation Database.

68. Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 Years: A Comparative Modeling Study of Risk. (PubMed)

Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 Years: A Comparative Modeling Study of Risk. Timing of initiation of screening for breast cancer is controversial in the United States.To determine the threshold relative risk (RR) at which the harm-benefit ratio of screening women aged 40 to 49 years equals that of biennial screening for women aged 50 to 74 years.Comparative modeling study.Surveillance, Epidemiology, and End Results program, Breast (...) Cancer Surveillance Consortium, and medical literature.A contemporary cohort of women eligible for routine screening.Lifetime.Societal.Mammography screening starting at age 40 versus 50 years with different screening methods (film, digital) and screening intervals (annual, biennial).life-years gained, breast cancer deaths averted; harms: false-positive mammography findings; harm-benefit ratios: false-positive findings/life-years gained, false-positive findings/deaths averted.Screening average-risk

Full Text available with Trip Pro

2012 Annals of Internal Medicine

69. Overdiagnosis of invasive breast cancer due to mammography screening: results from the norwegian screening program. (PubMed)

Overdiagnosis of invasive breast cancer due to mammography screening: results from the norwegian screening program. Precise quantification of overdiagnosis of breast cancer (defined as the percentage of cases of cancer that would not have become clinically apparent in a woman's lifetime without screening) due to mammography screening has been hampered by lack of valid comparison groups that identify incidence trends attributable to screening versus those due to temporal trends in incidence.To (...) estimate the percentage of overdiagnosis of breast cancer attributable to mammography screening.Comparison of invasive breast cancer incidence with and without screening.A nationwide mammography screening program in Norway (inviting women aged 50 to 69 years), gradually implemented from 1996 to 2005.The Norwegian female population.Concomitant incidence of invasive breast cancer from 1996 to 2005 in counties where the screening program was implemented compared with that in counties where the program

2012 Annals of Internal Medicine

70. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness

Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness Schousboe JT, Kerlikowske K, Loh A, Cummings SR Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of breast cancer screening, using mammography, at different intervals taking account of risk factors, such as age, breast density, history of breast biopsy, and family history

Full Text available with Trip Pro

2012 NHS Economic Evaluation Database.

71. Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. (PubMed)

Understanding recent trends in incidence of invasive breast cancer in Norway: age-period-cohort analysis based on registry data on mammography screening and hormone treatment use. To quantify the separate contributions of menopausal hormone treatment and mammography screening activities on trends in incidence of invasive breast cancer between 1987 and 2008.Population study using aggregated data analysed by an extended age-period-cohort model.Norway. Population Norwegian women aged 30-90 between (...) 1987 and 2008, including 50,102 newly diagnosed cases of invasive breast cancer. Main outcomes measures Attributable proportions of mammography screening and hormone treatment to recent incidence of invasive breast cancer, and the remaining variation in incidence after adjustment for mammography screening and hormone treatment.The incidence of invasive breast cancer in Norway increased steadily until 2002, levelled off, and then declined from 2006. All non-linear changes in incidence were explained

Full Text available with Trip Pro

2012 BMJ

72. Selenia dimensions digital tomosynthesis system (Hologic Inc.) for diagnostic mammography

Selenia dimensions digital tomosynthesis system (Hologic Inc.) for diagnostic mammography Selenia dimensions digital tomosynthesis system (Hologic Inc.) for diagnostic mammography Selenia dimensions digital tomosynthesis system (Hologic Inc.) for diagnostic mammography Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Selenia dimensions digital tomosynthesis (...) system (Hologic Inc.) for diagnostic mammography. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2012 Authors' conclusions Breast cancer is the most frequently diagnosed cancer in women and the second leading cause of cancer death after lung cancer. According to the American Cancer Society, 230,480 new cases of invasive breast cancer were diagnosed in 2011, and approximately 39,520 deaths were attributed to the disease. Despite widespread use and acceptance of cancer screening

2012 Health Technology Assessment (HTA) Database.

73. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. (PubMed)

Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. Annual ultrasound screening may detect small, node-negative breast cancers that are not seen on mammography. Magnetic resonance imaging (MRI) may reveal additional breast cancers missed by both mammography and ultrasound screening.To determine supplemental cancer detection yield of ultrasound and MRI in women at elevated risk for breast (...) cancer.From April 2004-February 2006, 2809 women at 21 sites with elevated cancer risk and dense breasts consented to 3 annual independent screens with mammography and ultrasound in randomized order. After 3 rounds of both screenings, 612 of 703 women who chose to undergo an MRI had complete data. The reference standard was defined as a combination of pathology (biopsy results that showed in situ or infiltrating ductal carcinoma or infiltrating lobular carcinoma in the breast or axillary lymph nodes

Full Text available with Trip Pro

2012 JAMA

74. Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. (PubMed)

Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. To quantify the magnitude of overdiagnosis from non-progressive disease detected by screening mammography, after adjustment for the potential for lead time bias, secular trend in the underlying risk of breast cancer, and opportunistic screening.Approximate bayesian computation analysis with a stochastic simulation model designed (...) to replicate standardised incidence rates of breast cancer. The model components included the lifetime probability of breast cancer, the natural course of breast cancer, and participation in organised and opportunistic mammography screening.Isère, a French administrative region with nearly 1.2 million inhabitants.All women living in Isère and aged 50-69 during 1991-2006.Overdiagnosis, defined as the proportion of non-progressive cancers among all cases of invasive cancer and carcinoma in situ detected 1991

Full Text available with Trip Pro

2011 BMJ

75. Is computer aided detection (CAD) cost effective in screening mammography? A model based on the CADET II study

Is computer aided detection (CAD) cost effective in screening mammography? A model based on the CADET II study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 NHS Economic Evaluation Database.

76. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. (PubMed)

Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. False-positive mammography results are common. Biennial screening may decrease the cumulative probability of false-positive results across many years of repeated screening but could also delay cancer diagnosis.To compare the cumulative probability of false-positive results and the stage distribution of incident breast cancer after 10 years of annual or biennial (...) screening mammography.Prospective cohort study.7 mammography registries in the National Cancer Institute-funded Breast Cancer Surveillance Consortium.169,456 women who underwent first screening mammography at age 40 to 59 years between 1994 and 2006 and 4492 women with incident invasive breast cancer diagnosed between 1996 and 2006.False-positive recalls and biopsy recommendations stage distribution of incident breast cancer.False-positive recall probability was 16.3% at first and 9.6% at subsequent

Full Text available with Trip Pro

2011 Annals of Internal Medicine

77. Comparative Effectiveness of Digital Versus Film-Screen Mammography in Community Practice in the United States: A Cohort Study. (PubMed)

Comparative Effectiveness of Digital Versus Film-Screen Mammography in Community Practice in the United States: A Cohort Study. Few studies have examined the comparative effectiveness of digital versus film-screen mammography in U.S. community practice.To determine whether the interpretive performance of digital and film-screen mammography differs.Prospective cohort study.Mammography facilities in the Breast Cancer Surveillance Consortium.329,261 women aged 40 to 79 years underwent 869 286 (...) mammograms (231 034 digital; 638 252 film-screen).Invasive cancer or ductal carcinoma in situ diagnosed within 12 months of a digital or film-screen examination and calculation of mammography sensitivity, specificity, cancer detection rates, and tumor outcomes.Overall, cancer detection rates and tumor characteristics were similar for digital and film-screen mammography, but the sensitivity and specificity of each modality varied by age, tumor characteristics, breast density, and menopausal status

Full Text available with Trip Pro

2011 Annals of Internal Medicine

78. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews, registry database analyses and economic evaluation

The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews, registry database analyses and economic evaluation The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews, registry database analyses and economic evaluation Journals Library An error has occurred in processing the XML document (...) of mammography alone every 12–24 months appearing to have the highest net benefits. To optimise the use of resources and achieve maximum patient benefit, women at a higher risk of developing ipsilateral breast tumour recurrence or metachronous contralateral breast cancer should be offered more comprehensive and more frequent surveillance. {{author}} {{($index An error has occurred in processing the XML document An error has occurred in processing the XML document {{metadata.Journal}} Volume

2011 NIHR HTA programme

79. Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. (PubMed)

Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. To determine the effect of mammography screening on surgical treatment for breast cancer.Comparative analysis of data from Norwegian cancer registry.Mammography screening, Norway (screening of women aged 50-69 was introduced sequentially from 1996 to 2004).35,408 women aged 40-79 with invasive breast cancer or ductal carcinoma in situ treated surgically from 1993

Full Text available with Trip Pro

2011 BMJ

80. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. (PubMed)

Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Current guidelines recommend mammography every 1 or 2 years starting at age 40 or 50 years, regardless of individual risk for breast cancer.To estimate the cost-effectiveness of mammography by age, breast density, history of breast biopsy, family history of breast cancer, and screening interval.Markov microsimulation model.Surveillance, Epidemiology, and End (...) Results program, Breast Cancer Surveillance Consortium, and the medical literature.U.S. women aged 40 to 49, 50 to 59, 60 to 69, and 70 to 79 years with initial mammography at age 40 years and breast density of Breast Imaging Reporting and Data System (BI-RADS) categories 1 to 4.Lifetime.National health payer.Mammography annually, biennially, or every 3 to 4 years or no mammography.Costs per quality-adjusted life-year (QALY) gained and number of women screened over 10 years to prevent 1 death from

Full Text available with Trip Pro

2011 Annals of Internal Medicine